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Abstract 
Background: It is well-established that nonalcoholic fatty liver disease (NAFLD) is associated with type 2 diabetes 
mellitus (T2DM). Complement-C1q TNF-related protein 5 (CTRP5) is a novel adipokine involved in the regulation of 
lipid and glucose metabolism. We aimed to assess plasma levels of CTRP5 in patients with NAFLD (n = 22), T2DM 
(n = 22) and NAFLD with T2DM (NAFLD + T2DM) (n = 22) in comparison with healthy subjects (n = 21) and also to 
study the association between CTRP5 levels and NAFLD and diabetes-related parameters.
Methods: All subjects underwent anthropometric assessment, biochemical evaluation and liver stiffness (LS) meas-
urement. Insulin resistance (IR) was determined by the homeostasis model assessment (HOMA). Plasma CTRP5 levels 
were measured by enzyme-linked immunosorbent assay.
Results: We found significantly lower plasma levels of CTRP5 in patients with NAFLD + T2DM, NAFLD and T2DM 
(122.52 ± 1.92, 124.7 ± 1.82 and 118.31 ± 1.99 ng/ml, respectively) in comparison with controls (164.96 ± 2.95 ng/
ml). In the whole study population, there was a significant negative correlations between CTRP5 and body mass index 
(r = −0.337; p = 0.002), fasting blood glucose (FBG) (r = −0.488; p < 0.001), triglyceride (TG) (r = −0.245; p = 0.031), 
HOMA-IR (r = −0.492; p < 0.001), insulin(r = −0.338; p = 0.002), LS (r = −0.544; p < 0.001), alanine aminotrans-
ferase (ALT) (r = −0.251; p = 0.027), waist-to-hip ratio (WHR) (r = −0.352; p = 0.002) and waist circumference (WC) 
(r = −0.357; p = 0.001). After adjustment for BMI, decrease in circulating levels of CTRP5 remained as a significant 
risk factor for NAFLD, T2DM and NAFLD + T2DM. The receiver operating characteristic (ROC) curves of circulating 
CTRP5 in predicting NAFLD and T2DM demonstrated an area under the curve (AUC) of 0.763 in T2DM, and 0.659 in 
NAFLD + T2DM.
Conclusions: It appears that the decreased levels of CTRP5 contribute to the increased risk of T2DM and NAFLD.
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Background
Nonalcoholic fatty liver disease (NAFLD) encompasses 
a range of clinicopathological conditions varying, from 
simple steatosis alone to nonalcoholic steatohepatitis, 
which could ultimately lead to the development of cir-
rhosis and hepatocellular carcinoma [1]. NAFLD is 
recognized as the major hepatic component of meta-
bolic syndrome, which affects a considerable propor-
tion of patients with obesity and type 2 diabetes mellitus 
(T2DM) [2–4]. Accumulating evidence indicates a strong 
association of insulin resistance and obesity with NAFLD 
pathogenesis [5, 6], although the precise mechanism 
remains unclear.
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One possible mechanism is the increase in production 
of proinflammatory cytokines (e.g. interleukine-6 and 
tumor necrosis factor alpha and change in secretion of 
several adipokines (e.g. visfatin, resistin, leptin and adi-
ponectin), which makes conditions favorable for steatosis 
development [7–10]. It has been reported that circulat-
ing adiponectin decreases in patients with NAFLD. Also, 
plasma adiponectin level is inversely correlated with 
hepatic fat stores and insulin resistance [11].
The members of the C1q/TNF-related protein (CTRP) 
family have recently been reported as proteins that 
share functional and structural similarity to adiponectin 
[12–14].
Up to now, 15 CTRP family members have been identi-
fied that play important roles in energy homeostasis and 
inflammation [12–14]. The involvement of CTRP fam-
ily members in the pathogenesis of several metabolic 
diseases such as T2DM, obesity and hepatic staetosis 
are recently beginning to be appreciated. For example, 
overexpression of CTRP1 caused improvement of insu-
lin sensitivity in transgenic mice [15]. There is also evi-
dence that transgenic  animal  models overexpressing 
CTRP3 are resistance to diet-induced steatosis and have 
low hepatic triglyceride content [16]. In addition, overex-
pression of CTRP9 in mice reduced hepatic and skeletal 
muscle triglyceride levels and improved hepatic steatosis 
in diet-induced obesity [17]. More recent clinical stud-
ies have reported that diabetic patients [18] and sub-
jects with metabolic syndrome [19] have higher serum 
levels of CTRP1 than normal controls. Another study 
demonstrated that CTRP3 levels increase in metabolic 
syndrome patients and are strongly related to cardio-
metabolic parameters [20]. Our recent data showed that 
circulating levels of CTRP1 are significantly increased in 
patients with NAFLD and T2DM compared to healthy 
subjects [21].
Among the CTRP family members, CTRP5 has been 
demonstrated to be an important molecule related to 
metabolism regulation [22]. CTRP5 is a protein with 
243-amino acids, consisting of N-terminal signal peptide 
followed by a collagen repeat, and a C-terminal globular 
domain [23, 24]. This protein is expressed by many tis-
sues including spleen, uterus, testis, brain, retinal pig-
ment, myocytes, and adipocytes, particularly in the 
stromal vascular cell fraction [25, 26] and was initially 
recognized as a molecule involved in late-onset macular 
degeneration and long anterior lens zonules [25]. It has 
been shown that CTRP5 induces phosphorylation of 
AMP-activated protein kinase (AMPK), thereby stimu-
lating glucose uptake and fatty acid oxidation [22]. More-
over, circulating CTRP5 is elevated in animal models of 
obesity-associated diabetes such as Otsuka Long-Evans 
Tokushima Fatty (OLETF) rats, ob/ob mice, and db/db 
mice [22]. It has been suggested that CTRP5 might be 
a human adipokine which circulates in large quantities 
in serum [27]. The single nucleotide polymorphism in 
3′-untranslated region of CTRP5 is also strongly associ-
ated with metabolic syndrome in Japanese people [28].
The role of CTRP5 in regulation of lipid and glu-
cose metabolism and its relationship with parameters 
related to energy metabolism have been shown in several 
experimental studies [22, 29] and in a limited number of 
human studies [27, 30, 31]. However, to our knowledge, 
no study has addressed the association of CTRP5 levels 
with NAFLD and metabolic- related profile in humans. It 
is also evident that T2DM is significantly associated with 
NAFLD pathogenesis. Hence, we aimed to investigate 
the circulating levels of CTRP5 in patients with NAFLD, 
T2DM and NAFLD with T2DM (NAFLD +  T2DM) in 
comparison with healthy subjects. We also intended to 
evaluate the possible association of CTRP5 level with 
several NAFLD and diabetes-related parameters.
Subjects and methods
Study population
A total of 87 subjects (all men) aged between 43 and 
72  years, were recruited for this case–control study as 
described previously [21]. The participants were selected 
among individuals who attended the outpatient clinic 
of Shariati Hospital, Tehran, Iran from March 2012 
until November 2013. The control group was selected 
from accompanying people of patients. The study sub-
jects were categorized into healthy subjects (controls) 
(n  =  21), NAFLD patients (n  =  22), NAFLD  +  T2DM 
patients (n = 22) and T2DM patients (n = 22).
T2DM diagnosis was based on American  Diabe-
tes  Association (ADA) criteria [32]. It should be men-
tioned that 6 patients with T2DM and 3 patients with 
NAFLD + T2DM were receiving anti-diabetic drugs. The 
mean duration of diabetes was 1.66 ± 0.65 years.
The participants with evidence of viral or autoimmune 
hepatitis, Wilson’s disease, primary biliary cirrhosis, 
haemochromatosis, congenital cardiac disease, infec-
tious disease, acute or chronic renal failure, malignan-
cies, type 1 diabetes mellitus and also a history of alcohol 
consumption of >30 g/day, were excluded from the study. 
In addition, all patients were free from taking medica-
tion causing steatosis (i.e., corticosteroids, valproic acid, 
amiodarone, estrogens, tamoxifen, amiodarone, valproic 
acid, diltiazem). Also, 2 patients with NAFLD, 6 ones 
with T2DM, and 6 patients with NAFLD + T2DM were 
receiving antihypertensive drugs. Diagnosis of NAFLD 
was established by a physician using a routine abdomi-
nal ultrasonography. Liver stiffness (LS), a noninvasive 
assessment of liver fibrosis, was measured by a Tran-
sient Elastogeraphy (Fibroscan® France). The study was 
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approved by Ethics Committee of the Tehran University 
of Medical Sciences (TUMS). Informed written consent 
was signed by all subjects before their participation in the 
study.
LS assessment
LS was measured by transient elastography using the 
FibroScan® 502 machine (EchoSense, Paris, France, 
5 MHz) as described previously [21]. Briefly, based on the 
manufacturer’s guidelines the M probe was used when 
the thoracic perimeter less than 110  cm, and the XL 
probe was used when the thoracic perimeter was 110 cm 
and above. The measurements were repeated at least 10 
times for each individual and the median value was cal-
culated. If the inter-quartile range (IQR) was less than 
30 % of the median reading, values were considered rep-
resentative of LS.
Anthropometric and clinical characterization
All participants underwent anthropometric assessment, 
ultrasonographic and biochemical evaluation. A self-
reported and standard questionnaire was used to collect 
demographic and socioeconomic characteristics, medical 
history and drug use from each participant.
The body mass index (BMI) was computed by divid-
ing the weight (in kilograms) with the square of height 
(in meters). Waist circumference (WC) was measured 
to the nearest 0.1 cm at the level of the iliac crest with a 
flexible inch tape while the subject was at minimal res-
piration. Hip measurements were taken at the maximum 
circumference of the buttocks. Waist-to-hip ratio (WHR) 
was  calculated  as waist circumference (in centimeters) 
divided by hip circumference (in centimeters). Homeo-
stasis model assessment of insulin resistance (HOMA-
IR) was calculated as follows: [fasting blood glucose (mg/
dL)] × [fasting blood insulin (µU/mL)/405]. Systolic and 
diastolic blood pressures of all participants were meas-
ured after 15 min rest in a sitting position with a manual 
sphygmomanometer.
Biochemical and laboratory measurements
Venous blood was collected following an overnight fast-
ing and divided into two aliquots, in clot activator tube 
and vacutainer containing EDTA, in order to biochemical 
analyses and CTRP5 measurement, respectively. Samples 
were centrifuged and serum and plasma were separated and 
either used immediately or stored at −80 °C until assayed. 
Fasting blood glucose (FBG) was  measured  using the glu-
cose  oxidase method. Insulin was assessed using enzyme 
linked immunosorbent assay (ELISA) kit (Monobind Inc., 
USA). Serum triglycerides (TG), high-density lipoprotein 
cholesterol (HDL-C), low-density lipoprotein cholesterol 
(LDL-C) and total cholesterol (TC), creatinin and urea were 
assessed using a commercially available kit (Pars Azmoon, 
Tehran, Iran). The levels of alanine amino transferase (ALT), 
aspartate amino transferase (AST), gamma glutamyl trans-
ferase (γ-GT) and alkaline phosphatase (ALP) were meas-
ured using enzymatic colorimetric assays (Pars Azmoon kit, 
Tehran, Iran). The blood cell-related indicators red blood 
cell (RBC), white blood cells (WBC), Hemoglobin, plate-
lets, mean corpuscular volume (MCV), and red cell distri-
bution width (RDW) were evaluated by automatic analyzer. 
The AST to platelet ratio index (APRI), as a noninvasive 
marker to assess liver fibrosis, was calculated as AST (IU/l)/
(upper limit of normal)/platelet count (×109/L) ×100 [33]. 
It should be noted that some data from this study were pub-
lished recently [21].
Plasma CTRP5 measurement
Plasma levels of CTRP5 were determined by immunoas-
say using Cayman system kit according to manufacturer’s 
protocol. The inter-assay variability and intra-assay vari-
ability were 6.975 and 6.3 %, respectively.
Statistical analysis
Data analysis was performed using SPSS 16 (SPSS, Chi-
cago, IL, USA). Descriptive analysis was applied and 
normality was tested using the Shapiro–Wilk test for all 
quantitative variables. The data of variables with normal 
distribution are expressed as mean ±  standard error of 
the means (SEM), and data of variables without normal 
distribution are expressed as median  ±  interquartile 
ranges (IQR). For data with normal distribution, compar-
isons among the four groups were done by the one-way 
ANOVA.
When significant  differences  were  found, the  Bonfer-
roni post hoc test was used for multiple comparisons.
For non-normally distributed variables, compari-
sons among the four groups were determined with 
the Kruskal–Wallis test. When significant  differ-
ences were  found, differences between two independent 
groups were determined by the Mann–Whitney U test. 
We used the Bonferroni correction to reduce the prob-
ability of spurious positives in multiple testing.
We also conducted multinomial logistic regression 
to investigate the risk of diseases (NAFLD, T2DM, and 
NAFLD + T2DM) regarding CTRP5, BMI, WC, hip, and 
WHR. Receiver operating characteristic (ROC) curve 
was also plotted using SPSS 16 to reflect the sensitivity 
and specificity of CTRP5 in order to evaluate their ability 
to differentiate the investigated diseases. The comparison 
of the area under the curve (AUC) was performed by a p 
value <0.05. The greater AUC represents the higher diag-
nostic value for CTRP5 to differentiate the diseases.
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Results
The anthropometric parameters and biochemical charac-
teristics of patients and control subjects are presented in 
Table 1.
No significant difference was found among individuals 
with NAFLD, T2DM, and NAFLD  +  T2DM groups in 
terms of age, TG, TC, HDL-C, LDL-C, LDL-C/HDL-C, 
cholesterol/HDL-C, ALP, urea, creatinin, systolic blood 
pressure (SBP), diastolic blood pressure (DBP), RBC, 
WBC, MCV, RDW, platelets and hemoglobin.
Based on one-way ANOVA; WC, hip, WHR, BMI, 
and LS were significantly different among the all stud-
ied groups. In addition, the Kruskal–Wallis test showed 
that there were significant differences in HOMA-IR, 
FBG, insulin, APRI, AST, ALT, and γ-GT among the 
all studied groups. Additional file  1: Table S1 shows 
the results of post hoc analysis for WC, hip, WHR, BMI, 
LS, HOMA-IR, FBG, insulin, APRI, AST, ALT, and γ-GT 
which were significantly different among the groups.
The plasma concentration of CTRP5 was depicted 
in Fig.  1. This adipokine was found to be significantly 
(p  <  0.001) lower in patients with NAFLD  +  T2DM 
compared with the controls (122.52  ±  1.92  ng/ml in 
NAFLD + T2DM patients, 164.96 ± 2.95 ng/ml in con-
trol subjects). In addition, the plasma concentration 
of CTRP5 was significantly lower in NAFLD patients 
Table 1 Anthropometric and laboratory characteristics of healthy subjects, NAFLD, T2DM and NAFLD + T2DM
Continuous variables with normal and non-normal distribution were described as mean ± SEM and median (IQR), respectively
NAFLD nonalcoholic fatty liver disease, T2DM type 2 diabetes mellitus, n number, WC waist circumference, WHR waist-to-hip ratio, BMI body mass index, FBG fasting 
blood glucose, HOMA-IR homeostasis model assessment of insulin resistance, TG triglycerides, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C 
low-density lipoprotein cholesterol, ALT alanine amino transferase, AST aspartate amino transferase, ɤ-GT gamma glutamyl transferase, ALP alkaline phosphatase, 
LS liver stiffness, SBP systolic blood pressure, DBP diastolic blood pressure, RBC red blood cell, WBC white blood cell, MCV mean corpuscular volume, RDW red cell 
distribution width, APRI aspartate amino transferase to platelet ratio index, ns non-significant
Characteristics Healthy subjects  
(N = 21)
NAFLD  
(N = 22)
T2DM  
(N = 22)
NAFLD + T2DM 
(N = 22)
Total difference 
p value
Age, years 51 (48–60) 51 (48–55) 57.5 (47–60) 52 (45–57) ns
WC, cm 93.29 ± 2.14 104.95 ± 1.49 100.43 ± 2.38 109.61 ± 2.23 <0.001
Hip, cm 99.29 ± 1.23 105.32 ± 1.2 100.77 ± 1.51 107.73 ± 73 <0.001
WHR, – 0.94 ± 0.01 1.00 ± 0.01 0.99 ± 0.02 1.02 ± 0.02 <0.001
BMI, kg/m2 24.76 ± 0.80 29.18 ± 0.50 27.28 ± 0.91 30.61 ± 0.84 <0.001
FBG, mg/dL 89.46 (84.10–96.56) 95.82 (90.10–100.70) 129.95 (123.20–175.20) 155 (127.00–187.95) <0.001
Insulin, µU/mL 3.5 (2.7–4.9) 9.6 (9.2–12) 6.35 (2.2–8.9) 8.5 (6.3–10.6) <0.001
HOMA-IR, – 0.75 (0.56–1.23) 2.32 (1.89–2.89) 2.46 (0.91–3.17) 2.64 (1.99–5.51) <0.001
TG, mg/dL 114.65 (89.95–154) 143.95 (109.1–164.8) 138.7 (105.3–163.7) 165.6 (113.75–241.05) ns
TC, mg/dL 190.01 ± 6.69 201.45 ± 7.64 195.84 ± 9.67 191.42 ± 16.17 ns
HDL-C, mg/dL 54.39 ± 2.78 48.61 ± 2.16 54.22 ± 2.88 49.79 ± 3.98 ns
LDL-C, mg/dL 111.65 ± 6.41 117.73 ± 7.75 113.76 ± 7.85 109.22 ± 10.53 ns
LDL-C/HDL-C, – 2.12 ± 0.14 2.42 ± 0.15 2.13 ± 0.13 2.04 ± 0.19 ns
TC/HDL-C, – 3.65 ± 0.16 4.24 ± 0.17 3.69 ± 0.14 3.59 ± 0.30 ns
Urea nitrogen, mg/dL 28.13 ± 1.17 32.29 ± 1.90 30.88 ± 1.33 30.98 ± 2.42 ns
Creatinin, mg/dL 1.27 ± 0.04 1.29 ± 0.04 1.25 ± 0.04 1.10 ± 0.08 ns
AST, U/L 17.1 (15.2–18.3) 22.1 (18.3–30.9) 16.55 (14.6–19.00) 24.6 (21.55–28.1) <0.001
ALT, U/L 15.3 (12.55–18.4) 28.9 (22.5–44.5) 15.6 (12.7–21.6) 41.75 (32.9–52.9) <0.001
γ-GT, U/L 19.9 (16.26–23.79) 28.96 (24.3–36.1) 23.49 (19.79–36.74) 36.97 (27.79–72.65) <0.001
ALP, U/L 224.5 (202–249) 231.5 (195–278) 243 (190–316) 228.5 (186.5–271) ns
SBP, mmHg 127.65 ± 4.43 130.84 ± 4.49 136.79 ± 4.53 137.02 ± 4.40 ns
DBP, mmHg 78.15 ± 2.37 84.39 ± 3.76 79.95 ± 2.50 80.70 ± 2.10 ns
LS, kPa 2.33 ± 0.48 5.46 ± 0.37 4.77 ± 0.32 7.00 ± 0.51 <0.001
RBC, ×1012/L 4.66 ± 0.11 4.9 ± 0.09 4.96 ± 0.09 4.96 ± 0.13 ns
Platelet, ×109/L 221.05 ± 11.63 223.91 ± 10.65 224.64 ± 9.21 240.1 ± 8.27 ns
APRI, – 0.22 (0.15–0.25) 0.28 (0.19–0.41) 0.18 (0.15–0.21) 0.24 (0.22–0.30) <0.05
WBC, ×109/L 5.5 (5.2–6.5) 5.5 (5.1–6.9) 6.6 (5.7–7.6) 6.65 (5.55–7.55) ns
Hemoglobin, g/dl 14 (12–15) 14 (14–15) 14.5 (12–16) 14 (12–15.5) ns
RDW, % 14 (14–15) 14 (14–14) 14.5 (14–15) 14 (14–15) ns
MCV, fL 87 (86–89) 85 (83–88) 84.5 (82–88) 82 (79–89) ns
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and T2DM subjects compared with the controls 
(124.7 ±  1.82  ng/ml in NAFLD; p  <  0.001 vs. controls; 
118.31 ± 1.99 ng/ml in T2DM; p < 0.001 vs. controls).
Results of multinomial logistic regression analysis dem-
onstrated the main effect of plasma level of CTRP5, WC, 
hip and WHR and BMI on the risk of all three conditions 
(Table  2). From the diagnostic standpoint, along with 
every 1 ng/ml decrease in CTRP5 level, NAFLD risk was 
significantly (p < 0.001) increased 662.25 times. Moreo-
ver, the risk of T2DM and NAFLD  +  T2DM were sig-
nificantly (p < 0.001) increased 714.28 and 684.93 times, 
respectively, along with every 1 ng/ml decrease in CTRP5 
level (Table 2a). After adjustment for WC (Table 2c), hip 
(Table 2f ), WHR (Table 2i) and BMI (Table 2l), decrease 
in circulating levels of CTRP5 remained as a significant 
risk factor for NAFLD, T2DM and NAFLD  +  T2DM 
although BMI-adjusted odd ratio (OR) and hip-adjusted 
OR were decreased by almost tenfold in comparison with 
before adjustment.
Based on logistic regression and significant likelihood 
ratio test (p < 0.0001); decreasing plasma levels of CTRP5 
showed a slight significant interaction with increasing 
WC values (Table  2d), increasing hip values (Table  2g), 
increasing WHR values (Table  2j) and increasing BMI 
values (Table 2m) for disease risk.
The ROC curves of CTRP5 circulating levels in pre-
dicting NAFLD, T2DM, and NAFLD  +  T2DM dem-
onstrated an area under the curve (AUC) of 0.428 in 
NAFLD, 0.659 in NAFLD + T2DM and 0.763 in T2DM. 
Interestingly, the ROC curve for decreasing levels of 
CTRP5 for T2DM (Fig.  2c) exhibited a good diagnostic 
feature. However, the ROC curve for decreasing levels of 
CTRP5 for NAFLD and NAFLD + T2DM (Fig. 2a, b) did 
not represent a good diagnostic feature, mainly because 
of poor specificity. To overcome this disadvantage, 
we provided a diagnostic algorithm (Fig.  3) based on 
CTRP5 levels and other laboratory measurements. 
Based on this diagnostic algorithm, CTRP5  <140  ng/
ml and FBG  <110  mg/dl showed astonishing diagnostic 
capabilities for NAFLD (sensitivity  =  95.45  %; specific-
ity = 95.38 %; positive predictive value (PPV) = 87.5 %, 
negative predictive value (NPV)  =  98.41  %). We also 
found that CTRP5  <140  ng/ml, FBG  ≥110  mg/dl, and 
LS  <5.5  kPa might be a plausible criteria to differenti-
ate T2DM individuals from NAFLD, NAFLD  +  T2DM 
and healthy individuals (sensitivity  =  80.95  %; specific-
ity = 89.35 %; PPV = 70.83 %, NPV = 93.65 %). The diag-
nostic algorithm (Fig.  3) showed CTRP5  <  140  ng/ml, 
FBG ≥ 110 mg/dl, and LS >5.5 kPa is a specific criteria to 
differentiate NAFLD + T2DM individuals from NAFLD, 
T2DM and healthy individuals (sensitivity  =  60.87  %; 
specificity = 93.75 %; PPV = 77.78 %, NPV = 86.96 %).
In the whole study population, CTRP5 circulating 
levels demonstrated a significant negative correlation 
with BMI (r = −0.337; p =  0.002), WHR (r = −0.352; 
p = 0.002) and WC (r = −0.357; p = 0.001) (Fig. 4b, c, h).
We also found a significant inverse correlation between 
CTRP5 levels and FBG (r = −0.488; p < 0.001), HOMA-
IR (r = −0.492; p < 0.001), insulin (r = −0.338; p = 0.002) 
and TG (r = −0.245; p = 0.031) (Fig. 4d, f, g, i).
Moreover, a significant inverse correlation was 
observed between plasma level of CTRP5 and ALT 
(r = −0.251; p = 0.027) and also between CTRP5 and LS 
(r = −0.544; p < 0.001) (Fig. 4a, e).
We also analyzed the possible effects of anti-diabetic 
and anti-hypertensive medications on plasma levels of 
CTRP5. We observed no significant differences regarding 
the interaction of status (groups)  ×  anti-diabetic treat-
ments or status  ×  anti-hypertensive medications (data 
not shown), hence we conducted analysis of covariance 
(ANCOVA) to remove possible effects of anti-diabetic 
and anti-hypertensive medications on plasma levels of 
CTRP5 (Table  3). As shown in this table, CTRP5 lev-
els were significantly different between the four studied 
groups after removing the possible effects of aforesaid 
medications.
Discussion
More recently, the importance of CTRP family members 
in the development of metabolic disorders is beginning 
to emerge from several studies [20, 30, 34]. However, the 
clinical relevance of CTRP5 in NAFLD and other diabe-
tes-related disorders is yet unknown. To our knowledge, 
this is the first study reporting a strong association of 
circulating levels of CTRP5 with NAFLD and T2DM in 
humans.
The main findings of this study are as follows: (1) circu-
lating levels of CTRP5 in patients with NAFLD, T2DM 
Fig. 1 The CTRP5 levels in patients with NAFLD, T2DM, and 
NAFLD + T2DM in comparison with control group (#p values < 0.001). 
Each bar represents mean ± SEM
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Table 2 Multinomial logistic regression for the association of CTRP5 (a) WC (b) hip (e), WHR (h) and BMI (k) with outcome 
risk of NAFLD, T2DM, and NAFLD + T2DM
Groups B SE Wald p value Odds ratio 95 % confidence  
interval for OR
Correct  
prediction (%)
a. Risk of outcomes along with each unit increase in CTRP5
 NAFLD −6.495 0.036 32,216.808 <0.001 0.00151 0.00141–0.00162 40.9
 T2DM −6.571 0.039 28,394.414 <0.001 0.00140 0.00130–0.00151 66.7
 NAFLD + T2DM −6.531 0 – – 0.00146 0.00146–0.001461 26.1
b. Risk of outcomes along with each unit increase in WC
 NAFLD 0.126 0.038 10.756 0.001 1.134 1.052–1.223 22.7
 T2DM 0.071 0.033 4.612 0.032 1.074 1.006–1.146 27.3
 NAFLD + T2DM 0.191 0.044 18.743 <0.001 1.210 1.110–1.319 54.5
c. Adjustment of CTRP5 risk for WC†
 NAFLD −6.486 0.039 28,258.994 <0.001 0.00152 0.00141–0.00164 47.6
 T2DM −6.555 0.043 23,663.923 <0.001 0.00142 0.00130–0.00154 52.4
 NAFLD + T2DM −6.522 <0.001 – – 0.001 0.001–0.001 47.4
d. Interaction risk (CTRP5 × WC) for each unit increase in CTRP5 and each unit increase of WC†
 NAFLD 0.0 0.0 11.289 0.001 0.999 0.99–1 52.4
 T2DM −0.001 0.0 20.162 <0.001 0.999 0.98–0.99 57.1
 NAFLD + T2DM 0.0 0.0 8.270 0.004 0.999 0.99–1 10.5
e. Risk of outcomes along with each unit increase in hip
 NAFLD 0.169 0.058 8.403 0.004 1.184 1.056–1.327 18.2
 T2DM 0.037 0.049 0.587 0.444 1.038 0.943–1.143 22.7
 NAFLD + T2DM 0.246 0.065 14.306 <0.001 1.279 1.126–1.453 54.5
f. Adjustment of CTRP5 risk for hip†
 NAFLD −4.922 0.038 16,351.610 <0.001 0.00728 0.00675–0.00785 47.6
 T2DM −4.994 0.043 13,373.185 <0.001 0.00677 0.00622–0.00737 52.4
 NAFLD + T2DM −4.953 0 – <0.001 0.00706 0.00706–0.00706 42.1
g. Interaction risk (CTRP5 × hip) for each unit increase in CTRP5 and each unit increase of hip †
 NAFLD −0.002 0.0005 13.028 <0.001 0.9983 0.9974–0.9992 66.7
 T2DM −0.003 0.001 23.169 <0.001 0.9974 0.9964–0.9984 61.9
 NAFLD + T2DM −0.0002 0.0005 13.013 <0.001 0.9983 0.9973–0.9992 0
h. Risk of outcomes along with each unit increase in WHR
 NAFLD 17.519 6.128 8.171 0.004 40,570,699.7 246.43–6.67 × 1012 63.6
 T2DM 16.808 6.191 7.372 0.007 19,938,468.5 107.2–3.7 × 1012 0
 NAFLD + T2DM 24.517 6.609 13.760 <0.001 44,428,129,710.6 105147.7–1.8 × 1016 57.1
i. Adjustment of CTRP5 risk for WHR†
 NAFLD −6.519 0.039 28,193.410 0.001 0.00147 0.00136–0.00159 61.9
 T2DM −6.588 0.041 25,291.299 0.001 0.00137 0.00126–0.00149 42.1
 NAFLD + T2DM −6.559 <0.001 – – 0.00141 0.00141–0.00141 38.9
j. Interaction risk (CTRP5 × WHR) for each unit increase in CTRP5 and each unit increase of WHR†
 NAFLD −0.161 0.043 14.026 <0.001 0.851 0.783–0.926 61.9
 T2DM −0.193 0.046 17.424 <0.001 0.824 0.753–0.903 52.6
 NAFLD + T2DM −0.151 0.043 12.6 <0.001 0.860 0.791–0.935 0
k. Risk of outcomes along with each unit increase in BMI
 NAFLD 0.338 0.101 11.155 0.001 1.403 1.150–1.711 31.8
 T2DM 0.173 0.087 3.976 0.046 1.189 1.003–1.409 27.3
 NAFLD + T2DM 0.500 0.117 18.150 <0.001 1.648 1.310–2.074 63.6
l. Adjustment of CTRP5 risk for BMI levels†
 NAFLD −4.243 0.038 12,261.550 <0.001 0.0144 0.0133–0.0155 47.6
 T2DM −4.308 0.043 10,259.458 <0.001 0.0134 0.0124–0.0146 57.1
 NAFLD + T2DM −4.283 <0.001 – – 0.0138 0.0138–0.0138 57.9
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and NAFLD  +  T2DM were markedly lower compared 
to the controls; (2) inverse correlations were observed 
between circulating CTRP5 levels and some parameters 
of glucose metabolism (FBG, insulin and HOMA-IR), fat 
mass (BMI, WC and WHR) and lipid metabolism (TG) 
in the whole population; (3) an inverse correlation was 
found between circulating level of CTRP5 and LS and 
also between CTRP5 and ALT; (4) decreased circulating 
CTRP5 levels were strongly associated with the increased 
risk of NAFLD, NAFLD + T2DM and T2DM.
Table 2 continued
Groups B SE Wald p value Odds ratio 95 % confidence  
interval for OR
Correct  
prediction (%)
m. Interaction risk (CTRP5 × BMI) for each unit increase in CTRP5 and each unit increase of BMI
 NAFLD −0.001 0.001 5.166 0.023 0.999 0.997–1.000 57.1
 T2DM −0.003 0.001 14.793 <0.001 0.997 0.996–0.999 61.9
 NAFLD + T2DM 0.000 0.001 2.864 0.091 0.999 0.998–1.000 0
Adjustment for risk of CTRP5 for the aforesaid outcome diseases by controlling for WC (c) hip (f ), WHR (i) and BMI (l) The interactive risk of increasing CTRP5 levels with 
WC (d) hip (g), WHR (j) and BMI (m) for the aforesaid outcome diseases
NAFLD non-alcoholic fatty liver disease, T2DM type 2 diabetes mellitus, CTRP5 complement-C1q TNF-related protein 5, BMI body mass index, WC waist circumference, 
WHR waist-to-hip ratio
† Likelihood Ratio Test: p value < 0.0001
Fig. 2 Receiver operating characteristic (ROC) curves for diagnosis NAFLD (a), NAFLD + T2DM (b), and T2DM patients (c) by CTRP5 levels. The 
comparison of the area under the curve (AUC) was performed by a p value <0.05
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Our findings of lower CTRP5 levels in patients than 
the controls are in contrast to studies showing that cir-
culating level of CTRP5 was elevated in animal models of 
diabetes [22]. A similar inconsistency has been also noted 
for other CTRPs such as CTRP 1 and CTRP3 [12, 15, 18]. 
The reason behind the discrepancy might be due to dif-
ferences between animal models and human studies. In 
details, animal models reflect certain aspects of a disease. 
For example, in some animal models; insulin resistance 
predominates, whilst in others β-cell failure is predomi-
nant [35]. However, it is well-established that T2DM 
and NAFLD are heterogeneous conditions that are not 
attributable to a certain pathophysiological mechanism. 
In fact, a constellation of interrelated abnormalities is 
involved in etiology of NAFLD and T2DM [35–37].
Our findings with regard to lack of difference in CTRP5 
levels among the patient groups, are in accordance with 
a recent study by Flehmig et  al. in which CTRP5 levels 
showed no significant difference between obese sub-
jects without diabetes compared to obese patients with 
diabetes [31]. Although it is difficult to dissect this find-
ing, the possible explanation for our results regarding 
lack of difference in CTRP5 levels among the patient 
groups, may lie in fact that there are shared mechanisms 
in the pathogenesis of NAFLD and T2DM. Specifically, 
their pathogenesis is the result of common combina-
tion of interrelated factors such as inflammation, oxida-
tive stress, obesity and insulin resistance [35, 36]. So, we 
have adjusted for BMI, WC, hip and WHR in multino-
mial logistic regression analysis to find out the possible 
role of obesity in the relationship of CTRP5 with T2DM 
and NAFLD. Although decrease in circulating levels of 
CTRP5 remained as a significant risk factor after adjust-
ment for BMI, WC, hip and WHR, but adjustment for 
BMI and hip resulted in a substantial attenuation of the 
association between CTRP5 and NAFLD and T2DM. 
Therefore, it could be deduced that the lack of difference 
in CTRP5 levels among the patient groups stemmed from 
the shared risk factors such as obesity in patient groups. 
However, further clinical studies with a large sample size 
are required to observe the possible difference among 
patient groups.
It has been reported that CTRP5 levels, along with 
other adipokines, are related to HOMA-IR which are 
in line with our correlation results [31]. However, in 
contrast to our results, Choi et  al. found no association 
between circulating CTRP5 levels and insulin resistance 
index and also other cardiometabolic risk factors [30]. 
Apart from HOMA-IR, the present study also showed 
inverse correlation between CTRP5 and some of obesity 
indices. We believe that different inclusion and exclusion 
criteria used in various human studies and complicated 
nature of NAFLD and T2DM might justify the discrep-
ancy among human studies.
Insulin resistance and obesity contribute to fatty liver 
development by altering production of adipokines and 
cytokines, change in amount of triglyceride synthesis, 
increasing lipolysis and subsequent delivery of free fatty 
acids to liver [35, 36, 38].
Although the exact mechanisms by which decreased 
CTRP5 levels are associated with the increased risk of 
NAFLD and T2DM cannot be ascertained according to 
the present study, several possibilities derived from the 
experimental studies should be considered. First, there 
is evidence that recombinant CTRP5 enhances GLUT4 
translocation and glucose uptake in myocytes [22]. Sec-
ondly, treatment of myocytes and liver cells with human 
CTRP5 increases fatty acid oxidation and concomitantly 
decreases fatty acid synthesis via activation of AMPK 
[22, 23]. Since disturbances in fatty acid oxidation and 
subsequent excessive lipid storage are closely associated 
with clinicopathological features in NAFLD [39, 40]; it 
can be speculated that the low CTRP5 level in patients 
contributes to impaired lipid homeostasis in NAFLD 
possibly through dysregulation of fatty acid oxidation. 
Thirdly, it has been reported that globular domain of 
CTRP5 ameliorates apoptosis and insulin resistance 
in palmitate-treated myocytes via inhibiting caspase-3 
activity, reactive oxygen species accumulation and insulin 
receptor substrate-1 (IRS-1) reduction [29]. On the other 
hand, multiple studies have suggested that accumula-
tion of excess saturated fatty acids in muscle cells causes 
oxidative stress, mitochondrial dysfunction and apopto-
sis, which all have been linked to insulin resistance [41, 
Fig. 3 Diagnostic algorithm for differentiating NAFLD, T2DM, 
NAFLD + T2DM and healthy individuals. CTRP5 complement-C1q 
TNF-related protein 5, FBG fasting blood glucose, AST aspartate 
aminotransferase, ALT alanine aminotransferase, LS liver stiffness, Sen 
sensitivity, Spec specificity, NPV negative predictive value, PPV positive 
predictive value
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Fig. 4 Graphic representation of correlations between CTRP5 levels and serum ALT (a), BMI (b), WHR (c), FBG (d), LS (e), HOMA-IR (f), Insulin (g), WC 
(h) and TG (i). Correlation coefficient (r) and p values are calculated by the Pearson correlation method
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42]. There is also evidence for the association between 
impaired skeletal muscle fatty acid metabolism and 
defects in the trafficking and translocation of GLUT4 
in skeletal muscle with insulin resistance and obesity 
[43, 44]. Based on the observations mentioned above, it 
is tempting to speculate that decreasing CTRP5 levels 
might contribute to NAFLD and T2DM through obesity 
and insulin resistance-dependent pathways; however we 
should not rule out the involvement of other unknown 
mechanisms.
Another important finding of this study is that circulat-
ing CTRP5 level is inversely correlated with LS (a marker 
of liver fibrosis) [45] and ALT (a marker of hepatic 
inflammation) [46]. Accordingly, it raises the possibility 
that decreased CTRP5 levels could be associated with 
inflammation and hepatocellular damage in NAFLD. 
However, the measurement  of  other  adipokines and 
inflammatory  markers is warranted to corroborate this 
concept.
By ROC analyses, CTRP5 demonstrated its value in 
T2DM diagnosis with good prediction ability. Conversely, 
CTRP5 alone was not a specific marker enabling us to 
distinguish NAFLD from T2DM and NAFLD + T2DM; 
however, astonishing diagnostic capability was obtained 
after considering LS and FBG. It should be mentioned 
that  future diagnostic  studies  are  required to evaluate 
diagnostic power of this criteria. Moreover, monitor-
ing of circulating levels of CTRP5 in response to current 
treatments, along with prospective studies might be help-
ful in this regard.
Although the current study along with the available 
literature partly provide novel insights into the role of 
CTRP5 as a possible contributory factor in the patho-
genesis of NAFLD and T2DM, our study was limited by a 
relatively small sample size. Moreover, our study design is 
cross-sectional, which precludes us from drawing infer-
ences about causality. Therefore, we acknowledge that 
further large-scale clinical investigations with longitudi-
nal data are needed to verify our findings. Furthermore, 
the measurement of the typical adipokine, adiponectin, 
can provide further support for our results. It should 
be noted that except for a limited number of studies in 
humans, the available literature regarding the role of 
CTRP5 in regulation of lipid and glucose metabolism are 
mainly restricted to animal studies and in  vitro experi-
ments. Therefore, it makes difficult the interpretation of 
our results and their comparison with other studies.
Collectively, an association between lower circulat-
ing levels of  CTRP5  and increased risk of NAFLD and 
T2DM was found in our study. The current study sug-
gests that the association between insulin resistance and 
NAFLD might mediate at least in part through the effects 
of low CTRP5. Also, it appears that assessment of CTRP5 
together with LS and FBG might be useful to distinguish 
patients with NAFLD from T2DM and NAFLD + T2DM. 
However, more experimental studies are necessary to 
understand the molecular details of the CTRP5 function 
in regulation of metabolic pathways.
Abbreviations
NAFLD: nonalcoholic fatty liver disease; T2DM: type 2 diabetes mellitus; CTRP5: 
C1q/TNF-related protein 5; WC: waist circumference; WHR: waist-to-hip ratio; 
BMI: body mass index; FBG: fasting blood glucose; HOMA-IR: homeostasis 
model assessment of insulin resistance; TG: triglycerides; TC: total cholesterol; 
HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein 
cholesterol; ALT: alanine amino transferase; AST: aspartate amino transferase; 
ɤ-GT: gamma glutamyl transferase; ALP: alkaline phosphatase; LS: liver stiff-
ness; SBP: systolic blood pressure; DBP: diastolic blood pressure; RBC: red 
blood cell; WBC: white blood cell; MCV: mean corpuscular volume; RDW: 
red cell distribution width; APRI: aspartate amino transferase to platelet ratio 
index; AMPK: AMP-activated protein kinase; SEM: standard error of mean; IQR: 
inter-quartile range; ROC: receiver operating characteristic; AUC: area under 
the curve.
Authors’ contributions
SE, HP and MD conceived of the study, participated in its design and wrote the 
manuscript. NM and RF carried out the immunoassays. MB, SE and PS partici-
pated in the acquisition and analysis of data. PS and HP edited the manuscript. 
All authors read and approved the final manuscript.
Additional file
Additional file 1: Table S1. The results of post hoc analysis for anthro-
pometric and laboratory characteristics which were significantly different 
among the four groups.
Table 3 A full factorial model of ANCOVA to adjust the possible effect of anti-diabetic and anti-hypertensive drugs on cir-
culating levels of CTRP5 in controls, NAFLD, T2DM and NAFLD + T2DM patients
NAFLD non-alcoholic fatty liver disease, T2DM type 2 diabetes mellitus, CTRP5 complement-C1q TNF-related protein 5, SEM standard error of mean
Status Status Mean difference (I − J) ± SEM p value 95 % confidence interval for  
difference
Lower bound Upper bound
Control NAFLD 40.208 ± 3.164 0.000 31.657 48.759
T2DM 45.197 ± 3.338 0.000 36.176 54.219
NAFLD + T2DM 42.926 ± 3.293 0.000 34.028 51.824
Page 11 of 12Emamgholipour et al. Diabetol Metab Syndr  (2015) 7:108 
Author details
1 Department of Clinical Biochemistry, Faculty of Medicine, Tehran University 
of Medical Sciences, Tehran, Iran. 2 Department of Clinical Biochemistry, Fac-
ulty of Medicine, Iran University of Medical Sciences, Tehran, Iran. 3 Students’ 
Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran. 
4 Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases 
Research Institute, Tehran University of Medical Sciences, Tehran, Iran. 
Acknowledgements
We are thankful to Digestive Diseases Research Institute of Tehran University of 
Medical Sciences for financial support of this study. The authors also thank all 
study staff who contributed time and effort to this study.
Competing interests
The authors declare that they have no competing interests.
Received: 27 May 2015   Accepted: 5 November 2015
References
 1. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease 
and hepatocellular carcinoma: a weighty connection. Hepatology. 
2010;51(5):1820–32.
 2. Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Meta-
bolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond). 
2009;116(7):539–64.
 3. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver 
disease: biochemical, metabolic, and clinical implications. Hepatology. 
2010;51(2):679–89.
 4. Sayki Arslan M, Turhan S, Dincer I, Mizrak D, Corapcioglu D, Idilman R. 
A potential link between endothelial function, cardiovascular risk, and 
metabolic syndrome in patients with Non-alcoholic fatty liver disease. 
Diabetol Metab Syndr. 2014;6:109.
 5. Cusi K. Role of obesity and lipotoxicity in the development of nonal-
coholic steatohepatitis: pathophysiology and clinical implications. Gastro-
enterology. 2012;142(4):711–25.
 6. Gariani K, Philippe J, Jornayvaz FR. Non-alcoholic fatty liver disease 
and insulin resistance: from bench to bedside. Diabetes Metab. 
2013;39(1):16–26.
 7. Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, 
et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Ali-
ment Pharmacol Ther. 2008;27(5):412–21.
 8. Bertolani C, Marra F. The role of adipokines in liver fibrosis. Pathophysiol-
ogy. 2008;15(2):91–101.
 9. Gatselis NK, Ntaios G, Makaritsis K, Dalekos GN. Adiponectin: a key play-
maker adipocytokine in non-alcoholic fatty liver disease. Clin Exp Med. 
2014;14(2):121–31.
 10. Paredes-Turrubiarte G, González-Chávez A, Pérez-Tamayo R, Salazar-
Vázquez BY, Hernández VS, Garibay-Nieto N et al. Severity of non-alco-
holic fatty liver disease is associated with high systemic levels of tumor 
necrosis factor alpha and low serum interleukin 10 in morbidly obese 
patients. Clin Exp Med. 2015:1-10.
 11. Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, de Iasio R, et al. 
Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin 
resistance and hepatic fat content, not to liver disease severity. J Clin 
Endocrinol Metab. 2005;90(6):3498–504.
 12. Schaffler A, Buechler C. CTRP family: linking immunity to metabolism. 
Trends Endocrinol Metab. 2012;23(4):194–204.
 13. Schaffler A, Scholmerich J, Salzberger B. Adipose tissue as an immuno-
logical organ: toll-like receptors, C1q/TNFs and CTRPs. Trends Immunol. 
2007;28(9):393–9.
 14. Seldin MM, Tan SY, Wong GW. Metabolic function of the CTRP family of 
hormones. Rev Endocr Metab Disord. 2014;15(2):111–23.
 15. Peterson JM, Aja S, Wei Z, Wong GW. CTRP1 protein enhances fatty acid 
oxidation via AMP-activated protein kinase (AMPK) activation and acetyl-
CoA carboxylase (ACC) inhibition. J Biol Chem. 2012;287(2):1576–87.
 16. Peterson JM, Seldin MM, Wei Z, Aja S, Wong GW. CTRP3 attenuates diet-
induced hepatic steatosis by regulating triglyceride metabolism. Am J 
Physiol Gastrointest Liver Physiol. 2013;305(3):G214–24.
 17. Peterson JM, Wei Z, Seldin MM, Byerly MS, Aja S, Wong GW. CTRP9 trans-
genic mice are protected from diet-induced obesity and metabolic dys-
function. Am J Physiol Regul Integr Comp Physiol. 2013;305(5):R522–33.
 18. Pan X, Lu T, Wu F, Jin L, Zhang Y, Shi L, et al. Circulating complement-C1q 
TNF-related protein 1 levels are increased in patients with type 2 diabetes 
and are associated with insulin sensitivity in Chinese subjects. PLoS One. 
2014;9(5):e94478.
 19. Chalupova L, Zakovska A, Adamcova K. Development of a novel enzyme-
linked immunosorbent assay (ELISA) for measurement of serum CTRP1: a 
pilot study: measurement of serum CTRP1 in healthy donors and patients 
with metabolic syndrome. Clin Biochem. 2013;46(1):73–8.
 20. Choi KM, Hwang SY, Hong HC, Yang SJ, Choi HY, Yoo HJ, et al. C1q/TNF-
related protein-3 (CTRP-3) and pigment epithelium-derived factor (PEDF) 
concentrations in patients with type 2 diabetes and metabolic syndrome. 
Diabetes. 2012;61(11):2932–6.
 21. Shabani P, Naeimi KH, Beigy M, Emamgholipour S, Parvaz E, Poustchi 
H, et al. Circulating level of CTRP1 in patients with nonalcoholic fatty 
liver disease (NAFLD): is it through insulin resistance? PLoS One. 
2015;10(3):e0118650.
 22. Park SY, Choi JH, Ryu HS, Pak YK, Park KS, Lee HK, et al. C1q tumor necrosis 
factor alpha-related protein isoform 5 is increased in mitochondrial DNA-
depleted myocytes and activates AMP-activated protein kinase. J Biol 
Chem. 2009;284(41):27780–9.
 23. Kim MJ, Lee W, Park EJ, Park SY. Role of hepatocyte nuclear factor-4alpha 
in transcriptional regulation of C1qTNF-related protein 5 in the liver. FEBS 
Lett. 2010;584(14):3080–4.
 24. Mandal MN, Vasireddy V, Reddy GB, Wang X, Moroi SE, Pattnaik BR, et al. 
CTRP5 is a membrane-associated and secretory protein in the RPE and 
ciliary body and the S163R mutation of CTRP5 impairs its secretion. Invest 
Ophthalmol Vis Sci. 2006;47(12):5501–13.
 25. Ayyagari R, Mandal MNA, Karoukis AJ, Chen L, McLaren NC, Lichter 
M, et al. Late-onset macular degeneration and long anterior lens 
zonules result from a CTRP5 gene mutation. Invest Ophthalmol Vis Sci. 
2005;46(9):3363–71.
 26. Wong GW, Krawczyk SA, Kitidis-Mitrokostas C, Revett T, Gimeno R, Lodish 
HF. Molecular, biochemical and functional characterizations of C1q/
TNF family members: adipose-tissue-selective expression patterns, 
regulation by PPAR-gamma agonist, cysteine-mediated oligomeriza-
tions, combinatorial associations and metabolic functions. Biochem J. 
2008;416(2):161–77.
 27. Schmid A, Kopp A, Aslanidis C, Wabitsch M, Müller M, Schäffler A. Regula-
tion and function of C1Q/TNF-related protein-5 (CTRP-5) in the context of 
adipocyte biology. Exp Clin Endocrinol Diabetes. 2013;121(05):310–7.
 28. Yamada Y, Ichihara S, Kato K, Yoshida T, Yokoi K, Matsuo H, et al. Genetic 
risk for metabolic syndrome: examination of candidate gene polymor-
phisms related to lipid metabolism in Japanese people. J Med Genet. 
2008;45(1):22–8.
 29. Yang WM, Lee W. CTRP5 ameliorates palmitate-induced apoptosis and 
insulin resistance through activation of AMPK and fatty acid oxidation. 
Biochem Biophys Res Commun. 2014;452(3):715–21.
 30. Choi HY, Park JW, Lee N, Hwang SY, Cho GJ, Hong HC, et al. Effects of a 
combined aerobic and resistance exercise program on C1q/TNF-related 
protein-3 (CTRP-3) and CTRP-5 levels. Diabetes Care. 2013;36(10):3321–7.
 31. Flehmig G, Scholz M, Kloting N, Fasshauer M, Tonjes A, Stumvoll M, et al. 
Identification of adipokine clusters related to parameters of fat mass, 
insulin sensitivity and inflammation. PLoS One. 2014;9(6):e99785.
 32. Association AD. Diagnosis and classification of diabetes mellitus. Diabetes 
Care. 2012;35(Suppl 1):S64–71.
 33. Yilmaz Y, Yonal O, Kurt R, Bayrak M, Aktas B, Ozdogan O. Noninvasive 
assessment of liver fibrosis with the aspartate transaminase to platelet 
ratio index (APRI): usefulness in patients with chronic liver disease: APRI in 
chronic liver disease. Hepat Mon. 2011;11(2):103–6.
 34. Deng W, Li C, Zhang Y, Zhao J, Yang M, Tian M, et al. Serum C1q/TNF-
related protein-3 (CTRP3) levels are decreased in obesity and hyperten-
sion and are negatively correlated with parameters of insulin resistance. 
Diabetol Metab Syndr. 2015;7:33.
 35. Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic 
fatty liver disease. Trends Endocrinol Metab. 2008;19(10):371–9.
 36. Noureddin M, Rinella ME. Nonalcoholic fatty liver disease, diabetes, 
obesity, and hepatocellular carcinoma. Clin Liver Dis. 2015;19(2):361–79.
Page 12 of 12Emamgholipour et al. Diabetol Metab Syndr  (2015) 7:108 
 37. Gaemers IC, Groen AK. New insights in the pathogenesis of non-alcoholic 
fatty liver disease. Curr Opin Lipidol. 2006;17(3):268–73.
 38. Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the 
pathogenetic roles of insulin resistance and adipocytokines. Curr Mol 
Med. 2009;9(3):299–314.
 39. Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in 
non-alcoholic fatty liver disease. J Gastroenterol. 2013;48(4):434–41.
 40. Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P, et al. 
Increase in long-chain polyunsaturated fatty acid n − 6/n − 3 ratio in 
relation to hepatic steatosis in patients with non-alcoholic fatty liver 
disease. Clin Sci (Lond). 2004;106(6):635–43.
 41. Martins AR, Nachbar RT, Gorjao R, Vinolo MA, Festuccia WT, Lambertucci 
RH, et al. Mechanisms underlying skeletal muscle insulin resistance 
induced by fatty acids: importance of the mitochondrial function. Lipids 
Health Dis. 2012;11:30.
 42. Yuzefovych L, Wilson G, Rachek L. Different effects of oleate vs. palmitate 
on mitochondrial function, apoptosis, and insulin signaling in L6 skeletal 
muscle cells: role of oxidative stress. Am J Physiol Endocrinol Metab. 
2010;299(6):E1096–105.
 43. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, et al. 
Mechanism of free fatty acid-induced insulin resistance in humans. J Clin 
Investig. 1996;97(12):2859.
 44. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Investig. 
2000;106(4):473.
 45. Coco B, Oliveri F, Maina A, Ciccorossi P, Sacco R, Colombatto P, et al. Tran-
sient elastography: a new surrogate marker of liver fibrosis influenced by 
major changes of transaminases. J Viral Hepatitis. 2007;14(5):360–9.
 46. Suzuki A, Lymp J, Sauver JS, Angulo P, Lindor K. Values and limitations of 
serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. 
Liver Int. 2006;26(10):1209–16.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
